TP53 and cancer: Wei et al. demonstrated that ATF3 (activating transcription factor 3) whose expression is suppressed by mutant p53, disrupts the interaction between mutant p53 and TAp63, and thus sensitizes tumor cells bearing p53 mutation to anti-cancer drugs [52].